ScholarWorks@Gachon: Eom, Joong Sik

Detailed Information

Eom, Joong Sik (엄중식)

College of Medicine (Department of Medicine)

Research Area

Tel 032-458-2789
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

COVID19:13||SARSCoV2:9||Infection control:4||Mortality:3||regdanvimab:2||Rheumatic diseases:2||Cross infection:2||Risk Factors:2||Treatment:2||Outbreak:2||CTP59:2||Prevention and control:2||Coronavirus:2||Recommendations:2||Young:2||Bacteremia:2||Critical:2||colistin:2||Ciclesonide:1||Clinical:1||Clinical Trial:1||Colistimethate sodium:1||Computed tomography:1||Conjunctiva:1||Construction:1||Countermeasures:1||Disease severity:1||ESBL:1||Effectiveness:1||Enteritis:1||Environmental microbiology:1||Facilities:1||Foodwater borne pathogens:1||Guideline:1||Healthcare worker:1||Healthcareassociated infection:1||Highrisk exposure:1||Humoral immunity:1||Incidence:1||Indwelling Catheters:1||Influenza:1||Influenza Virus:1||Inhalation:1||Intensive care units:1||Intervention:1||Korea:1||Longterm care facility:1||Lymphoma:1||Masks:1||Middle East respiratory syndrome coronavirus:1||Multidrug resistance:1||Mycobacterium opium complex:1||Nanoparticle vaccine:1||Neutrophil gelatinaseassociated lipocalin:1||NonPharmacological Intervention:1||Omicron:1||Omicron Variant:1||Onehealth surveillance:1||Oriental eye worm:1||Outbreak in healthcare workers:1||Parasites:1||Peramivir:1||Personal protective equipment:1||Postexposure prophylaxis:1||Preisolation pneumonia:1||Predictor:1||Pregnancy:1||Premature birth:1||Preparedness:1||Prognostic factor:1||Pyelonephritis:1||Recombinant protein vaccine:1||Remdesivir:1||Respiratory Support:1||Respiratory Viruses:1||Rhino Virus:1||SARSCoV2 Omicron Variant:1||SARSCoV2 Virus:1||Safety:1||Screening:1||Sepsis:1||Severe:1||South Korea:1||Surgery:1||Surveillance:1||System:1||TMP/SMX:1||The fee for infection prevention and control:1||Thelazia callipaeda:1||Tracking:1||UTI:1||Vaccine Efficacy:1||Vancomycinresistant:1||Virologic:1||Wastewaterbased epidemiology:1||XBB.1.5:1||administration:1||carbapenemresistant Acinetobacter baumannii:1||cleaning:1||combination therapy:1||cost:1||disinfection:1||effectiveness:1||fever:1||human:1||influenza:1||intravenous:1||logistic regression:1||mRNA Vaccine:1||meropenem:1||oral antibiotics:1||oseltamivir:1||outcome:1||outpatient treatment:1||pneumonia:1||protection:1||pyelonephritis:1||response:1||risk factor:1||sterilization:1||tertiary hospital:1||therapeutics:1||treatment:1||vaccine:1||멸균:1||병원 감염:1||비용보상:1||세척:1||.:1||소독:1||Acinetobacter baumannii:1||Acquired immunodeficiency syndrome:1||Acute kidney injury:1||AntiSARSCoV2 monoclonal antibody:1||Antiviral:1||Antiviral agents:1||Bacteria:1||Biomarker:1||COVID19 HCW symptom surveillance:1||COVID19 treatment:1||CRAB:1||Campylobacter jejuni:1||Carbapenemresistant:1||Carbapenemaseproducing enterobacteriaceae:1||CatheterAssociated Urinary Tract Infection:1||Catheterassociated urinary tract infection:1||Cellular immunity:1||

STATISTICS: Total View :4,135,363; Today View :2,924

RSS_1.0 RSS_2.0 ATOM_1.0

1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE